HaiHe Biopharma

Executive Summary

HaiHe Biopharma is a clinical-stage biotechnology company based in Shanghai, China, focused on discovering and developing innovative biologic drugs for cancer treatment, particularly monoclonal antibodies and antibody-drug conjugates (ADCs). Founded in 2011, the company aims to address unmet medical needs in oncology by advancing novel antibody-based therapies through preclinical and clinical development. While HaiHe is privately held and does not disclose detailed financials, its focus on ADCs—a rapidly growing class of targeted cancer therapies—positions it within a competitive yet high-potential segment. The company's stage is Phase 1, indicating early clinical validation with limited publicly available data. As a private entity, HaiHe's progress is closely watched by investors seeking exposure to China's biotech innovation. The company's commitment to transformative treatments could yield significant value if clinical data demonstrate favorable safety and efficacy profiles.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Data Readout for Lead ADC Candidate30% success
• Q2 2027IND Filing for Second-Generation ADC50% success
• TBDPartnership or Licensing Deal for Novel Bispecific Antibody20% success